Abstract: Sleep disturbances are prevalent in patients with Alzheimer's disease (AD), being one of the most troubling symptoms during the progression of disease. However, little research has been made to determine if impaired sleep patterns appear years before AD diagnosis. This study tries to shed light on this issue by performing polysomnographic recordings in healthy elders and patients with mild cognitive impairment (MCI). We further investigated whether changes in sleep patterns parallel memory decline as well as its relationship with the Apolipoprotein E (ApoE) 4 genotype. Results showed a significant shortening of rapid eye movement (REM) sleep together with increased fragmentations of slow-wave sleep in MCI patients relative to healthy elders. Interestingly, we further showed that reduction of REM sleep in MCI patients with ApoE 4 was more noticeable than in 4 non-carriers. Contrary to our initial hypothesis, changes in sleep patterns were not correlated with memory performance in MCI patients. Instead, increased REM sleep accompanied enhanced immediate recall in MCI 4 non-carriers. Taken together, these results suggest that sleep disruptions are evident years before diagnosis of AD, which may have implications for early detection of dementia and/or therapeutic management of sleep complaints in MCI patients.
INTRODUCTION
Aging is associated with progressive impairment of the organism's functional capacity, from cells to systems. With advancing age, a progressive loss of coordination among circadian systems and external inputs results in an advanced phase of the circadian cycle [1] , which leads to earlier sleep onset and earlier morning waking in elderly subjects [2] . In line with these findings, previous studies have reported agerelated volume reductions of the ventrolateral preoptic (VLPO) nucleus [3] , an anterior hypothalamic structure critically involved in sleep onset and maintenance [4] . The aforementioned results might contribute to increased sleep fragmentation [5] and slow-wave sleep (SWS) deficits found in older adults [6] . Therefore, evidence suggests that neural systems governing regulation and maintenance of sleepwake cycle are particularly vulnerable to senescence [7] , and might be caused by age-related neural impairments [8] .
Accumulating evidence suggest a high prevalence of sleep disorders in age-related neurodegenerative conditions as Parkinson [9] , dementia with Lewy bodies [10] , frontotemporal dementia [11] , and Alzheimer's disease (AD) [12] [13] [14] [15] [16] . AD patients, depending on disease severity, have shown impaired sleep patterns ranging from sleep fragmentation to decreased time spent in SWS and/or rapid eye movement (REM) sleep [17] . However, whether these altered sleep patterns precede AD diagnosis remains controversial to date.
Elders with mild cognitive impairment (MCI) show a significant decline in memory over time beyond what is expected from normal aging. In fact, 19% to 50% of individuals with MCI progress to dementia (typically AD) over a period of 3 years [18] . The belief that MCI represents the prodromal stage of AD has received strong support from neuropathological [19, 20] , biochemical [21] , neuroimaging [22, 23] , and neurophysiological studies [24, 25] . To the best of our knowledge, only one study has explored nocturnal sleep patterns in MCI patients by performing polysomnographic (PSG) recordings [26] . Authors found no significant changes in sleep structure of MCI patients when compared to age-matched controls, which might be due in part to the small and heterogeneous sample employed in that study. In contrast, a recent meta-analysis study has revealed that 17-59% of MCI patients reported sleep problems [27] . This controversy highlights the need of determining whether elders with MCI also exhibit objective alterations in sleep patterns, which may have implications for early diagnosis of AD and preliminary therapeutic management of sleep complaints in these patients.
The presence of the allele 4 in the apolipoprotein (ApoE) gene is the major genetic risk factor for AD [28] , and it predicts the rate of cognitive decline in elderly subjects [29] . Previous studies have reported significant changes of melatonin levels in AD patients with different ApoE polymorphisms [30] , suggesting a potential relationship between hormonal regulation of the sleep-wake cycle and ApoE car-rier status in AD. Recent studies, based on either actigraph recordings [31] or self-reports [32] , have tried to relate the ApoE 4 genotype to sleep disturbances in AD patients, but results appeared contradictory. Consequently, further PSG studies in MCI patients are clearly needed to verify the combined value of ApoE 4 genotype and sleep patterns as an early marker of AD.
The objective of the present study is threefold. First of all, to determine whether sleep patterns differ between healthy old persons and elders with MCI. Secondly, to evaluate the potential impact of ApoE 4 genotype on sleep structure of MCI patients. And thirdly, to examine whether there is a relationship between memory performance and sleep/wake parameters in healthy elders and MCI patients.
MATERIALS AND METHODS

Subjects
Twenty-five MCI patients (7 females, mean age: 70.5 ± 6.8 yr) and 25 healthy old (HO) volunteers (13 females, mean age: 67.1 ± 5.3 yr) were recruited from the Dementia Unit of the University Hospital Virgen del Rocio and the local community, respectively. HO participants and MCI patients were included in the study on a first-come, firstserved basis. Demographic profiles of the two groups are shown in Table 1 . All subjects provided written informed consent prior to their participation in the study. Experimental protocols were previously approved by the Ethical Committee for Clinical Investigations at the University Hospital Virgen del Rocio, and the Ethical Committee for Human Research at the University Pablo de Olavide. Research procedures were conducted in accordance with the Helsinki Declaration.
The diagnosis of amnestic MCI was based on consensus criteria [33] : (i) subjective memory complaints corroborated by the informant, (ii) objective memory decline evidenced by neuropsychological tests (scorings 1.5 standard deviations below the age-appropriate mean). Immediate and delayed recall were assessed with the Spanish version of the Logical Memory subtest extracted from the Wechsler Memory ScaleThird Edition (WMS-III), (iii) global score of 0.5 (questionable dementia) in the clinical dementia rating (CDR), (iv) normal independence function, judged both clinically and by means of the interview for deterioration in daily living activities (IDDD) validated in the Spanish population [34] , and (v) not meeting DSM-IV criteria for dementia. Global cognitive status was assessed with the Mini Mental State Examination (MMSE). Depression was excluded by the Geriatric Depression Scale (GDS) (shorter version) [35] . The GDS cut off was 5. MCI patients were not taking cholinesterase inhibitors at the time of recruiting. Inclusion criteria for HO subjects were (i) absence of objective memory decline as revealed by the same neuropsychological tests used with MCI patients, (ii) CDR global score of 0 (no dementia), and (iii) normal independent function judged clinically and by means of the IDDD. Depression was excluded by the GDS using the same criteria as for MCI patients.
All participants underwent a neurological exploration to rule out obvious neurological diseases. Furthermore, cerebral magnetic resonance imaging (MRI) was performed in both HO subjects and MCI patients to determine structural lesions such as territorial cerebral infarction, brain tumor, hippocampal sclerosis, and vascular malformation. Those with periventricular or deep white matter ischemia, as revealed by scorings above 1 on the Fazekas ischemic scale [36] , were excluded from the study. Participants reporting a history of neurological, psychiatric disorders, and/or major medical illness (chronic renal, hepatic, pulmonary or endocrine) were also excluded. The use of medication known to affect the sleep-wake cycle (benzodiazepines, tricyclic, or serotonin reuptake inhibitor antidepressants) was also considered cause for exclusion, both in HO and MCI patients. The absence of secondary causes of cognitive deficits was assessed by laboratory tests including complete blood count, blood chemistry, vitamin B12/folate, and thyroid function tests. Participants reported no complaints of sleep-disordered breathing, movement disorders during sleep or unusual sleep schedules (i.e., Table 1 (i.e., shift work), which was corroborated by their bed partners and/or caregivers. The Epworth Sleepiness Scale (ESS) was administered to HO subjects and MCI patients to establish the level of subjective daytime sleepiness [37] .
Apolipoprotein E Genotyping
Genomic DNA was extracted from peripheral blood using short proteinase K digestion. ApoE genotype was determined by conventional PCR (polymerase chain reaction) methods, using protocols previously described [38] .
Polysomnographic Recordings
Participants were admitted to the laboratory at 17:00h for electrode application. Time of lights-out was based on the individual's habitual bedtime, and confirmed by bed partners-caregivers. All subjects were instructed to follow their normal daily routine, take their usual meals, and to refrain from the intake of alcohol for 24 h prior to the study. The day of the experiment, subjects were not allowed to nap.
The PSG protocol included simultaneous recordings of electroencephalography (EEG), vertical and horizontal electrooculography (EOG), and electromyography (EMG) of submental muscles. All these physiological measures are required for sleep staging purposes. Respiratory measures were not collected because all participants reported no complaints of sleep-disordered breathing, corroborated by their bed partners, and ESS scorings below the cut off for suspecting sleep disorders associated with excessive daytime sleepiness. EEG was recorded from scalp locations referred to linked-mastoids. Electrode-scalp impedance was kept below 5 K . Vertical and horizontal EOG recordings were performed with pairs of electrodes placed above and below the left eye, and 1 cm apart from the outer canthus of each eye, respectively. EOG was recorded from a pair of electrodes placed on chin muscles (3 cm apart). All recordings were performed with gold cup, 10 mm diameter electrodes (Grass, Inc.) filled with electrolytic cream, and attached with either surgical tape (face placements) or collodion (scalp placements). PSG recordings were performed in a soundattenuated bedroom under infrared video-controlled supervision.
All electrophysiological measures were amplified (BrainAmp MR, Brain Vision ® ), filtered (0.1-100 Hz bandpass), digitized (250 Hz, 16-bit resolution), and stored in digital format for off-line analysis. Scoring of sleep stages (20-seconds EEG epochs) was conducted blindly by a trained technician according to standard guidelines [39] , based on the following montage: Fp1, Fp2, F3, F4, Fz, C3, C4, Cz, P3, P4, Pz, O1, O2, EMG and EOG. This electrode montage allowed us to reliably determine EEG features intrinsic to each sleep stage as well as EEG arousals. Scoring criteria for EEG arousals were taken from the American Sleep Disorders Association report [40] , and the level of sleep disruption was determined with the arousal index (AI). This index resulted from dividing the number of arousals in a sleep stage by the time (in hours) spent in that sleep stage. Statistical analyses included the following dependent variables: Total sleep time (TST, time spent in sleep stages), percent of SWS, REM, wake after sleep onset (WASO, wake from the sleep onset to the last sleep epoch before the wakeup time), and the AI for SWS and REM sleep.
Statistical Analysis
A logarithmic transformation was applied to nonnormally distributed dependent variables to approach normal distribution. Gender differences between groups (HO versus MCI; MCI 4 non-carriers versus MCI 4 carriers) were evaluated by applying the chi-square test, whereas the remaining demographic and cognitive variables were assessed with the Student T-test ( Table 1) . The Sidak-Bonferroni procedure was applied to correct for multiple comparisons.
A multivariate analysis of covariance (MANCOVA) was computed to study group differences in sleep/wake parameters introducing age as the only covariate, since years of education and levels of daytime sleepiness (ESS scorings) did not reach statistical significance. The effect on each dependent variable was evaluated with post-hoc analyses derived from analyses of covariance (ANCOVAs).
Multivariate regression (MVAR) analyses were used to determine whether selected sleep/wake variables predicted memory performance (immediate and/or delayed recall) in any of the groups (HO, MCI, MCI 4 carriers, and MCI 4 non-carriers). Next, we performed a multiple regression analysis with each single sleep/wake variable by eliminating the amount of the variation explained by age to establish if that sleep/wake variable significantly predicted memory performance. If the sleep/wake predictor reached significance in at least one of the two groups (HO and/or MCI; MCI 4-carriers and/or MCI 4 non-carriers), then we tested if the relationship between memory performance and the sleep/ wake parameter differed between the two groups (as revealed by differences between regression slopes). Statistical significance was defined as p<0.05. All statistical analyses were performed with SPSS v. 15 (SPSS Inc., Chicago, IL).
RESULTS
Demographic Variables
HO subjects and MCI patients showed a similar demographic profile ( Table 1) . Differences between MCI 4 carriers and non-carriers were only evident for age (p<0.01). The presence of ApoE 4 has been associated with a major risk of AD in MCI patients [28, 41] . In our study, 11 MCI patients were ApoE 4 heterozygote ( 3/ 4, n = 9; 2/ 4, n = 2) and the remaining 14 MCI patients were 4 non-carriers ( 3/ 3, n = 12; 2/ 3, n = 2). Overall, the prevalence of the ApoE 4 allele was 3.6-fold greater in MCI patients than in HO, and it was present in 44% of our MCI sample in contrast to the 12% observed in HO subjects. Distribution of the ApoE 4 genotype in our MCI sample resulted from chance; the presence of ApoE 4 allele was not employed as an inclusion criterion during the recruiting process.
Memory Function and Sleep/Wake Variables
MCI patients showed a significant memory decline in immediate (p<10 -6 ) and delayed recall (p<10 -8 ) when compared to HO ( Sleep patterns of our HO sample are in agreement with those previously reported [42, 43] . Table 2 summarizes sleep/wake measures in HO and MCI patients, and in MCI 4 carriers and non-carriers. Age was introduced as a covariate due to significant correlations with sleep/wake parameters (Pillai's trace, F 6,42 =2.5, p<0.03). No significant relationship was found between ESS scorings and sleep/wake parameters, indirectly supporting the absence of sleep-related breathing disorders associated with excessive daytime sleepiness in our study population.
The MANCOVA yielded significant group differences in sleep/wake parameters (Pillai's trace, F 6,42 =3.2, p<0.01). Further ANCOVAs confirmed that SWS was significantly disrupted in MCI patients as revealed by the higher density of arousals showed during this cerebral state (F 1,47 =9.8, p<0.003). We further found that REM sleep was shortened by approximately 5% in MCI when compared to HO (F 1,47 =8.1, p<0.007). Although REM reduction was even more prominent in MCI 4 carriers than in non-carriers (F 1,23 =6.2, p<0.02), this effect didn't reach significance. Fig. (1) shows differences in sleep-wake parameters between HO and MCI, and between MCI 4 carriers and non-carriers.
Relationships between Sleep/Wake Parameters and Cognition
Neither SWS arousals nor REM percentage predicted cognitive decline in HO and/or MCI patients. As REM sleep was significantly shortened in MCI 4 carriers when compared to non-carriers (p<0.02, uncorrected for multiple comparisons), we evaluated whether this reduction predicted memory performance in both subgroups of MCI patients.
This analysis confirmed a positive relationship between REM sleep and memory impairment for immediate recall, but only for MCI 4 non-carriers (F 2,11 = 6.3, p<0.01, adjusted R squared = 0.45, beta = 0.63, p<0.01). Comparison of regression slopes between MCI 4 carriers and non-carriers confirmed significant differences between the two groups (F 4,20 = 7.1, p<0.001, adjusted R squared = 0.5, beta for the interaction term = 1.3, p<0.006). Fig. (2) illustrates the regression slopes for MCI 4 carriers and non-carriers after accounting for age.
DISCUSSION
The present study provides the first evidence of impaired sleep patterns in elders with MCI. MCI patients showed reduced amounts of REM sleep and increased fragmentation of SWS. REM sleep deficits in MCI patients were aggravated by the presence of the ApoE 4 genotype, but the relationship between REM shortening and memory performance was only evident in MCI 4 non-carriers. Overall, these findings suggest that sleep patterns are affected years before AD diagnosis, which may have implications for early detection of dementia and/or therapeutic management of sleep disturbances in MCI patients.
Pioneering evidence has shown that wake duration correlates positively with accumulation of amyloid-beta (Abeta) and with increased levels of orexin [44] , a neuropeptide synthesized in neurons of the lateral hypothalamic area which projects to and inhibits the VLPO nucleus, critical for the maintenance of wakefulness [45] . We hypothesize that sleep loss (increased wake duration) caused by SWS fragmentation in MCI patients might contribute to facilitate molecular pathways involved in the production of toxic amyloid oligomers for years in a silent but irreversible manner. Two lines of evidence support this hypothesis. Firstly, sleep loss caused by excessive sleep fragmentation has been previously reported in mild-to-moderate AD patients [15, 16] , and it is aggravated as a function of dementia severity [14] . And secondly, recent studies suggest that aging. 
Fig. (2).
Scatter plot of partial correlation (after eliminating variations explained by age) displaying a significant positive correlation between REM percentage and immediate memory performance in MCI e4 carriers (triangles) and no significant correlation between the same variables in MCI e4 non-carriers (circles).
together with sleep loss impairs the response of the endoplasmic reticulum to cellular stress, leading to protein misfolding, accumulation, and aggregation [46] . Both misfolded proteins and the maladaptive response of the endoplasmic reticulum have been reported as common features in a broad range of neurodegenerative diseases [47, 48] , including AD [49, 50] . Consequently, increased sleep disruptions in MCI patients could exacerbate protein aggregation acting as a positive feedback in these conditions [51] . Whether increased SWS fragmentation contributes to exacerbate the progress to AD or it is just a consequence of molecular processes accompanying incipient neurodegeneration is a timely question that should be addressed in future studies.
The suprachiasmatic nucleus (SCN) is the primary circadian pacemaker in the mammalian brain and plays a central role in the generation and control of biological rhythms [52] . Previous studies have shown that VLPO and SCN are indirectly connected via the medial preoptic area, dorsomedial [53] , and dorsolateral hypothalamic nuclei [54] , suggesting that synaptic coordination between the two structures may play a critical role in the onset and maintenance of sleep-wake states. Post mortem evidence derived from MCI and AD patients has shown that degeneration of the retina-SCN-pineal axis may underlie such changes [55] . Therefore, difficulties of MCI patients for maintaining sleep continuity might be facilitated by structural damage and/or loss of synaptic efficacy between circadian structures and sleep-active neurons of VLPO nucleus.
To our knowledge, this study provides the first evidence of REM sleep reduction in MCI patients, particularly evident in MCI 4 carriers. Previous evidence also showed decreased REM sleep in AD patients [13-15, 26, 56,57] , although significant REM shortening was reported in only two studies [14, 57] . This controversy might be partially due to the small sample size used in these studies [13, 26] and/or to the intake of cholinesterase inhibitors at the time of sleep experiments [26] . This line of reasoning is supported by other studies that adequately controlled both variables [14, 57] . Quantitative EEG analyses has further revealed that spectral power composition of REM sleep differentiated AD patients from healthy elderly subjects [58] [59] [60] , which points to REM sleep as a vulnerable cerebral state featuring AD. Two different hypotheses could account for these results. Firstly, neurons of the nucleus basalis of Meynert release the greatest level of acetylcholine to the neocortex during REM sleep [61] playing a major role in regulating cortical EEG activation characteristic of this cerebral state [62] . Converging evidence suggests that cholinergic neurons of nucleus basalis of Meynert are selectively vulnerable to neurodegeneration in AD patients [63] and MCI [23] . Therefore, it seems plausible that cholinergic dysfunctions originated in the nucleus basalis of Meynert was partially responsible for REM deficits observed in MCI, and extended to AD patients. Secondly, it is largely accepted that REM generation mechanisms involve the pontine cholinergic network [64] . AD post mortem studies have shown morphological changes in mesopontine cholinergic neurons of the pedunculopontine and laterodorsal tegmentum [65] [66] [67] providing strong support to REM deficits reported in AD patients. Our findings suggest that neural mechanisms involved in the generation and/or maintenance of REM sleep may be functionally impaired years before AD diagnosis, MCI 4-carriers being more affected than non-carriers, which could be used in combination with biological and neuroimaging markers of early neurodegeneration to better determine boundaries between healthy aging and the prodromal stage of AD.
Previous studies have explored potential links between changes in sleep patterns and cognitive decline in AD patients. For instance, Moe and collaborators [16] reported significant correlations between cognitive and PSG measures (WASO, SWS, and REM) supporting the predictive value of this relationship in AD patients with different levels of disease severity. Sleep propensity has also shown to be inversely related to lower scores in global cognitive status, psychomotor, and memory function in mild to moderate AD patients [57] . In addition, increased REM sleep was found to correlate positively with enhanced cognitive function in patients with mild to moderate AD after donepezil administration [68] . Relationships between sleep patterns and cognitive decline in MCI patients had not been explored to date. Our study showed significant associations between immediate recall and REM sleep in MCI 4 non-carriers, supporting the combined role of REM sleep together with memory performance as a potential early marker of AD. However, no significant relationship was found between delayed recall and REM sleep in MCI patients with or without the ApoE 4 genotype. By using actigraph recordings, Yesavage and collaborators [31] also found significant relationships between deterioration of sleep parameters and lower MMSE scorings in AD 4 non-carriers. However, it is unclear why impaired cognitive function and sleep disturbances are more frequently related to the lack of the 4 allele in the ApoE gene. Previous evidence suggests that the most rapid cognitive decline occurs in AD patients with early onset 4 noncarriers [69] . It may happen that our MCI sample included patients who will develop AD with both early and late onset as well as persons who will not progress to AD. This heterogeneity might indeed influence the impact of the ApoE 4 genotype on cognitive decline and sleep disturbances. Further longitudinal studies are needed to better understand the combined role that ApoE 4 and disturbed sleep patterns play in prodromal stages of AD.
Evidence suggests that prevalence of sleep disturbances in MCI is elevated [27, 70, 71] , although most of the studies have been based on interviews with the patients and/or the bed partner and on administration of different neuropsychiatric scales. To our knowledge, only one study has explored the presence of sleep disorders in MCI patients by using PSG recordings [12] . Authors concluded that sleeprelated breathing disorders and sleep movement disorders are more prevalent in MCI patients. Unfortunately, our study cannot exclude the presence of sleep apnea and/or periodic limb movements on the basis of PSG recordings, which might partially confound our results. In our favour is the fact that all participants and their bed partners reported no related symptoms associated with these disorders during the neurologic exploration. Furthermore, subjective levels of daytime sleepiness were similar in both groups, individual ESS scorings were in all cases below the cut off for suspecting sleep disorders associated with excessive daytime sleepiness, and they were not significantly correlated with either cognitive or sleep/wake variables considered in our study. Nevertheless, further PSG studies including polygraphic respiratory and movement measures are needed to definitively confirm whether altered sleep patterns observed in MCI patients have a neurodegenerative basis or, in contrast, are due to sleep disorders exacerbated in healthy elders and MCI patients.
CONCLUSIONS
This study reveals altered sleep patterns in MCI patients, selectively aggravated for REM sleep in MCI 4 carriers. These results in combination with biological and neuroimaging markers of early neurodegeneration might contribute to establish the boundaries between healthy and pathological aging in humans. Important questions for future research include how sleep impairments evolve along the continuum of healthy aging to severe AD, and how sleep markers could be of help for improving early diagnosis of AD and for managing sleep disorders during progression to AD. Further longitudinal studies are also required to validate the complex relationship among sleep, ApoE 4 genotype, and early neurodegeneration.
